Stockscreener 앱 받기
11.78
6.79%
0.7358
전일 마감가:
$11.04
열려 있는:
$11.22
하루 거래량:
2.64M
Relative Volume:
1.52
시가총액:
$1.04B
수익:
$71.64M
순이익/손실:
$-294.57M
주가수익비율:
-3.5173
EPS:
-3.348
순현금흐름:
$-84.46M
1주 성능:
+7.47%
1개월 성능:
+34.90%
6개월 성능:
+18.25%
1년 성능:
+107.57%
1일 변동 폭
$11.03
$11.98
1주일 범위
$10.65
$11.98
52주 변동 폭
$5.45
$12.49
Kura Oncology Inc Stock (KURA) Company Profile
명칭
Kura Oncology Inc
전화
(858) 500-8800
주소
4930 DIRECTORS PLACE, SUITE 500, SAN DIEGO, CA
Compare KURA vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
KURA
Kura Oncology Inc
|
11.77 | 985.40M | 71.64M | -294.57M | -84.46M | -3.348 |
VRTX
Vertex Pharmaceuticals Inc
|
524.24 | 134.02B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
672.56 | 68.59B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
921.42 | 58.44B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
320.37 | 41.76B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
191.67 | 40.23B | 742.00K | -1.37B | -1.07B | -7.0731 |
Kura Oncology Inc Stock (KURA) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-04-14 | 개시 | Lake Street | Buy |
| 2025-09-04 | 개시 | Guggenheim | Neutral |
| 2025-02-06 | 다운그레이드 | BTIG Research | Buy → Neutral |
| 2024-10-24 | 개시 | UBS | Buy |
| 2024-10-14 | 다운그레이드 | Stifel | Buy → Hold |
| 2023-12-22 | 개시 | Mizuho | Buy |
| 2023-08-11 | 개시 | BofA Securities | Buy |
| 2023-07-27 | 개시 | Scotiabank | Sector Perform |
| 2023-05-17 | 개시 | BTIG Research | Buy |
| 2023-01-31 | 개시 | Stifel | Buy |
| 2022-07-12 | 개시 | Cantor Fitzgerald | Overweight |
| 2022-02-15 | 개시 | Jefferies | Buy |
| 2021-05-05 | 재개 | Credit Suisse | Outperform |
| 2021-04-26 | 재개 | Credit Suisse | Outperform |
| 2020-12-07 | 재확인 | H.C. Wainwright | Buy |
| 2020-12-03 | 개시 | Stifel | Buy |
| 2020-11-05 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
| 2020-07-07 | 개시 | Credit Suisse | Outperform |
| 2020-05-05 | 개시 | Barclays | Overweight |
| 2019-07-18 | 개시 | Deutsche Bank | Buy |
| 2018-11-09 | 개시 | Piper Jaffray | Overweight |
| 2018-08-01 | 개시 | H.C. Wainwright | Buy |
| 2016-10-13 | 재개 | Leerink Partners | Outperform |
| 2016-01-22 | 개시 | JMP Securities | Mkt Outperform |
| 2015-12-30 | 개시 | Oppenheimer | Outperform |
| 2015-12-16 | 개시 | Citigroup | Buy |
모두보기
Kura Oncology Inc 주식(KURA)의 최신 뉴스
Kura Oncology outlines targeted cancer pipeline as investors watch clinical milestones - AD HOC NEWS
Kura Oncology offers stock options to five new hires - Stock Titan
KURA News | KURA ONCOLOGY INC (NASDAQ:KURA) - ChartMill
Kura Oncology Reports Q1 2026 Results: Full Earnings Call Transcript - Benzinga
Kura Oncology reports $5.8 million revenue in Q1 2026 - scanx.trade
Kura Oncology, Inc.(NasdaqGS:KURA) added to Russell Small Cap Comp Growth Benchmark - marketscreener.com
Kura Oncology, Inc.(NasdaqGS: KURA) added to Russell 2500 Growth Benchmark - marketscreener.com
Kura Oncology, Inc.(NasdaqGS:KURA) dropped from Russell Small Cap Comp Value Benchmark - marketscreener.com
Kura Oncology, Inc.(NasdaqGS: KURA) dropped from Russell 3000 Value Benchmark - marketscreener.com
Kura Oncology, Inc. Actuals & Estimates (NASDAQ:KURA) - TradingView
Kura Oncology, Inc. Actuals & Estimates (HAM:KUR) - TradingView
Kura Oncology, Inc. liabilities 2021-2025 - Statista
Kura Oncology, Inc. Actuals & Estimates (DUS:KUR) - TradingView
KURA Forecast — Price Target — Prediction for 2027 - TradingView
Why Did KURA Stock Jump 13% In Pre-Market Today? - Stocktwits
Mizuho Securities Maintains Kura Oncology(KURA.US) With Buy Rating, Maintains Target Price $25 - Moomoo
Insiders At Kura Oncology Sold US$1.5m In Stock, Alluding To Potential Weakness - 富途牛牛
Kura Oncology CMO Mollie Leoni sells $834,283 in common stock By Investing.com - Investing.com Australia
Form 4 Kura Oncology Inc For: 22 June By Investing.com - Investing.com Nigeria
Kura Oncology CMO Mollie Leoni sells $834,283 in common stock - Investing.com
Kura Oncology (NASDAQ: KURA) CMO sells 84,929 shares in trading plan - Stock Titan
Understanding the Setup: (KURA) and Scalable Risk - Stock Traders Daily
[144] Kura Oncology, Inc. SEC Filing - Stock Titan
Kura Oncology Inc (KURA) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Kura Oncology Inc (KURA) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Kura Oncology Inc (KURA) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Kura Oncology Inc (KURA) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Kura Oncology Inc (KURA) Institutional Confidence - TradingKey
Kura Oncology Inc (KURA) Valuation: PE, PB & Fair Value Analysis - TradingKey
Kura Oncology Inc (KURA) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Kura Oncology Inc (KURA) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Kura Oncology Inc (KURA) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
KURA Reiterates by Citizens -- Price Target Maintained at $24.00 - GuruFocus
Citizens reiterates Kura Oncology stock rating on strong trial data By Investing.com - Investing.com South Africa
Citizens reiterates Kura Oncology stock rating on strong trial data - Investing.com
LifeSci Capital Maintains Kura Oncology(KURA.US) With Buy Rating, Maintains Target Price $28 - Moomoo
symbol__ Stock Quote Price and Forecast - CNN
Analysts’ Top Healthcare Picks: MBX Biosciences, Inc. (MBX), Kura Oncology (KURA) - The Globe and Mail
Kura Oncology, Inc. (KURA) Presents at European Hematology Association (EHA) 2026 CongressSlideshow - Seeking Alpha
H.C. Wainwright Maintains Kura Oncology(KURA.US) With Buy Rating, Maintains Target Price $40 - Moomoo
KURA: Ziftomenib plus 7+3 shows high response and survival rates in AML, supporting phase III trials - TradingView
KURA: Ziftomenib plus 7+3 shows high, durable remission and survival in AML, supporting phase III trials - TradingView
KURA: Ziftomenib demonstrates high remission rates and strong safety in AML, supporting global expansion - TradingView
Kura Oncology Inc EHA Investor Event Transcript - GuruFocus
Number of shareholders of Kura Oncology, Inc. – NASDAQ:KURA - TradingView
Kura Oncology And Kyowa Kirin Report Encouraging Long-Term Results For Ziftomenib And 7+3 Combination In Newly Diagnosed AML - marketscreener.com
Kura Oncology And Kyowa Kirin Report Encouraging Long-Term - GlobeNewswire
Kura Oncology Reports Inducement Grants under Nasdaq Listing Rule 5635(4) - marketscreener.com
The Technical Signals Behind (KURA) That Institutions Follow - Stock Traders Daily
How The Kura Oncology (KURA) Investment Narrative Is Evolving Without New Analyst Revisions - Yahoo Finance
Kura Oncology, Inc. (KURA) Discusses Clinical Data and Updated Development Strategy for DarlifarnibSlideshow - Seeking Alpha
Kura Oncology Inc (KURA) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.18%
2.70%
자본화:
|
볼륨(24시간):